• News
  • SAN DIEGO
  • BioTech

Mallinckrodt to acquire Cadence Pharmaceuticals for $1.21B

The health care products company Mallinckrodt is buying San Diego-based Cadence Pharmaceuticals (Nasdaq: CADX) for about $1.21 billion in a bid to strengthen its specialty drugs unit.

Cadence focuses on the commercialization of products for use in hospitals. It makes Ofirmev, an injectable version of the drug acetaminophen, the active ingredient in Tylenol. Ofirmev has been used to treat an estimated 6 million to 7 million patients since its launch in January 2011.

“The acquisition of Cadence Pharmaceuticals is consistent with our goal of becoming a leading global specialty pharmaceuticals company,” said CEO Mark Trudeau.

Shares of Cadence Pharmaceuticals Inc. surged $3.04, or 27.5 percent, to $14.11 in premarket trading Tuesday.

Ireland's Mallinckrodt PLC will pay $14 per share, a 27 percent premium to the Monday closing price of $11.07 for Cadence. The companies value the deal closer to $1.3 billion.

The boards of both companies have approved the deal that would make Cadence Pharmaceuticals Inc. a subsidiary at Mallinckrodt.

Mallinckrodt said Tuesday that it expects the acquisition, expected to close in March, to add to its adjusted earnings per share this year, and significantly add to adjusted earnings per share in 2015.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Cadence Pharmaceuticals Inc.

Company Website

12481 High Bluff Dr. Ste., 200
San Diego, CA 92130

Cadence Pharmaceuticals Inc. Executive(s):

Theodore Schroeder

  • Chief Executive Officer, President

Related Articles